PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Clinical trials for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
MS drug ocrevus put to the test in everyday practice
Disease control CompletedThis study followed 1,710 people with relapsing or primary progressive multiple sclerosis who were prescribed ocrelizumab (Ocrevus) as part of their normal care. Researchers tracked symptoms like fatigue, mobility, and cognition, as well as side effects, to see how well the drug …
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Cord blood cells injected into spine show promise for MS
Disease control CompletedThis early-stage trial tested a new cell therapy called DUOC-01, made from donated umbilical cord blood, in 20 adults with primary progressive multiple sclerosis (PPMS). The cells were injected into the spinal fluid to see if it was safe. Researchers also looked for early signs o…
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE1 • Sponsor: Joanne Kurtzberg, MD • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug shows promise in slowing progressive MS disability
Disease control CompletedThis Phase 3 trial tested whether the oral drug tolebrutinib can delay disability progression in people with primary progressive multiple sclerosis (PPMS). 767 adults with PPMS received either tolebrutinib or a placebo. The study measured time to confirmed disability worsening ov…
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Gold nanoparticles tested as brain energy boost for MS
Disease control CompletedThis phase 2 trial tested a liquid suspension of gold nanocrystals, called CNM-Au8, in 33 people with relapsing multiple sclerosis. The goal was to see if the treatment could improve energy metabolism in brain cells, measured by a special MRI scan. Participants took the drug by m…
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Eye camera spots hidden inflammation in MS patients
Knowledge-focused CompletedThis study used a special eye camera (adaptive optics) to look at blood vessel inflammation in the retina of 50 people with multiple sclerosis (MS) and healthy volunteers. The goal was to see if this inflammation differs between MS types and could serve as an early marker of dise…
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: NA • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Ocrelizumab's brain impact in progressive MS examined
Knowledge-focused CompletedThis study analyzed MRI scans from 732 people with primary-progressive multiple sclerosis who took part in the ORATORIO trial. Researchers wanted to see if ocrelizumab changes a part of the brain called the choroid plexus, which may be involved in inflammation. The study was obse…
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Sponsor: State University of New York at Buffalo • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Does your background affect your MS treatment? new study investigates
Knowledge-focused CompletedThis study reviewed medical records of 800 multiple sclerosis patients to see if gender, race, or socioeconomic status affected how quickly they started Ocrelizumab or how well it worked. Researchers looked at relapse rates and MRI changes over 12 to 24 months. The goal was to id…
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Blood tests may help unravel mysterious MS variants
Knowledge-focused CompletedThis completed study measured two proteins in the blood—neurofilament light chain and GFAP—that can signal nerve damage. Researchers compared 15 people with atypical MS, 30 with typical MS, and 15 healthy controls to see if these markers differ. The goal was to better understand …
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC